Morgan Stanley analyst Terence Flynn maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today and ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Structure Therapeutics Inc. - Depositary ...

Citizens JMP lowered the firm’s price target on Structure Therapeutics (GPCR) to $87 from $91 and keeps an Outperform rating on the shares.

William Blair started coverage on shares of Structure Therapeutics (NASDAQ:GPCR – Free Report) in a research note published on Friday, Marketbeat Ratings reports. The brokerage issued an outperform ...

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has released its Q4 earnings. Here is a breakdown of the information Structure ...

The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?

ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling ...

In trading on Wednesday, shares of Structure Therapeutics Inc (Symbol: GPCR) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $19.61 per share.

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) was the recipient of a significant growth in short interest in the month of January.As of January 15th, there was short interest ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Structure Therapeutics wasn’t one of them. The 10 stocks that ...